Navigation Links
Covance Reports Third Quarter Net Revenue Of $607 Million, Pro Forma EPS Of $0.83 And Adjusted Net Orders Of $732 Million
Date:10/29/2013

PRINCETON, N.J., Oct. 29, 2013 /PRNewswire/ -- Covance Inc. (NYSE: CVD) today reported results for its third quarter ended September 30, 2013.  Net revenue was $606.7 million, representing 11.4% growth from the third quarter of 2012's GAAP result of $544.8 million, and 12.0% growth from the third quarter of 2012's pro forma result of $541.9 million.  On a GAAP basis, the company reported earnings of $0.78 per diluted share in the third quarter of 2013 as compared to GAAP earnings of $0.69 in the third quarter of 2012.  Excluding charges associated with restructuring and other cost reduction actions totaling $4.9 million, the company reported earnings per diluted share of $0.83, up 15.8% over the pro forma earnings of $0.72 for the third quarter of 2012. 

"Financial highlights in the third quarter included consolidated pro forma revenue growth of 12%, operating margin of 11.1%, EPS of $0.83, and record quarterly free cash flow of $180 million. Our better-than-expected results in the third quarter were driven by exceptional performance in our central laboratory and continued strong results in clinical development," said Joe Herring, Chairman and Chief Executive Officer. "Strong commercial execution continued in the third quarter, as we delivered adjusted net orders of $732 million and an adjusted net book-to-bill of 1.21 to 1.  

"Late-Stage Development revenue grew 19% year-on-year to $386 million and pro forma operating margins were 22.6%, up 260 basis points from a year ago and 120 basis points from last quarter.  Better-than-expected kit volumes and a richer mix in central laboratories drove year-over-year revenue growth of 26%, while clinical development grew revenue 14% year-on-year. Both service lines expanded margins year-over-year and sequentially.

"In Early Development, revenue grew $6 million sequentially to $220 million, an increase of 1% from last year's pro forma result. Performance was led by clinical pharmacology, which delivered strong year-over-year and sequential revenue growth and margin expansion, more than offsetting year-over-year declines in discovery support services and pharmaceutical chemistry services. Pro forma operating margin increased 70 basis points year-on-year, and 180 basis points sequentially. Toxicology, where revenue declined slightly both year-on-year and sequentially, delivered better-than-forecasted orders in the third quarter, setting up expected sequential and year-on-year growth in the fourth quarter.

"Looking ahead to the fourth quarter of 2013, we expect sequential growth in revenue and operating income in both our Early and Late-Stage development segments, despite increased spending on our strategic IT programs. Accordingly, we are increasing our full-year pro forma diluted earnings per share target to approximately $3.20 (excluding gains on sale, costs associated with our ongoing restructuring activities, and assuming foreign exchange rates remain at September 30, 2013 levels), versus our previous expectation of $3.10 to $3.20. We also now expect full-year revenue growth of approximately 10%." 

Consolidated Results ($ in millions except EPS)3Q133Q12ChangeYTD13YTD12ChangeTotal Revenues

$647.0

$597.6$1,925.3

$1,756.6Less: Reimbursable Out-of-Pockets 

$40.3

$52.8$146.1

$138.2Net Revenues

$606.7

$544.8

11.4%

$1,779.2

$1,618.4

9.9%Operating Income

$62.6

$30.6

104.7%

$162.4

$72.8

123.1%Operating Margin

10.3%

5.6%9.1%

4.5%Net Income

$44.2

$37.8

16.9%

$133.4

$60.8

119.2%Earnings per Share

$0.78

$0.69

13.3%

$2.35

$1.07

119.0%Revenue from facilities closed in 2012**

-

$2.9-

$7.3Net Revenue, continuing ops*

$606.7

$541.9

12.0%

$1,779.2

$1,611.2

10.4%Restructuring Costs and other items

($4.9)

($18.1)($17.1)

($66.5)Loss from facilities closed in 2012**

-

($2.6)-

($6.4)Operating Income, excluding items*

$67.5

$51.3

31.7%

$ 179.5

$145.7

23.2%  Operating Margin, excluding items*

11.1%

9.5%10.1%

9.0%Gain on Sale of Investments

-

$1.5$16.4

$1.5Impairment of Equity Investment

-

--

($7.4)Favorable Income Tax Developments

-

$11.5-

$11.5Net Income, excluding items*

$47.3

$39.6

19.4%

$134.1

$111.6

20.1%Diluted EPS, excluding items*

$0.83

$0.72

15.8%

$2.36

$1.97

20.0%* See attached pro forma income statements for reconciliation of 2013 and 2012 GAAP to pro forma amounts.
** Facilities closed in 2012 include Chandler, Honolulu, and Basel.Operating Segment Results Early Development ($ in millions)3Q133Q12ChangeYTD13YTD12ChangeNet Revenues

$220.4

$220.7

(0.2%)

$642.2

$652.1

(1.5%)Operating Income (Loss)

$27.2

$7.1

283.3%

$65.6

($14.7)Operating Margin

12.3%

3.2%10.2%

(2.3%)Revenue from facilities closed in 2012**

-

$2.9-

$7.3Net Revenue, continuing ops

$220.4

$217.8

1.2%

$642.2

$644.8

(0.4%)Restructuring Costs and other items

($1.6)

($17.2)($7.5)

($65.1)Loss from facilities closed in 2012**

-

($2.6)-

($6.4)Operating Income, excluding items

$28.8

$26.9

7.0%

$73.1

$56.9

28.6%Operating Margin, excluding items

13.1%

12.4%11.4%

8.8%** Facilities closed in 2012 include Chandler, Honolulu, and Basel.The Early Development segment includes preclinical toxicology, analytical chemistry, clinical pharmacology, discovery support, and research products.  Net revenues in the third quarter of 2013 were $220.4 million, compared to $220.7 million on a GAAP basis and $217.8 million on a pro forma basis in the third quarter of last year. Last year's pro forma revenue excluded $2.9 million in revenue from the three sites closed by the end of 2012. On a pro forma basis, net revenue increased 1.2%, including a 10 basis point foreign exchange tailwind, as strong growth in clinical pharmacology and research products were largely offset by declines in discovery support and pharmaceutical chemistry. Sequential growth of $5.8 million was primarily driven by growth in clinical pharmacology and research products.

GAAP operating income in the third quarter of 2013 was $27.2 million, and included $1.6 million in costs associated with our previously-announced restructuring actions versus operating income of $7.1 million in the third quarter of 2012, which included losses at facilities closed in 2012 of $2.6 million and restructuring costs of $17.2 million.  Pro forma operating income, excluding these costs, was $28.8 million in the third quarter of this year, a 7.0% increase from the $26.9 million reported in the third quarter of 2012.  Pro forma operating margins were 13.1% in the third quarter of 2013, versus 12.4% in the third quarter of 2012 and 11.3% last quarter.

On a sequential basis, operating margin was positively impacted by the shift to above margin treatment of the UK R&D tax credit which added 200 basis points.  In addition, annual salary merit increases went into effect on July 1 and this negatively impacted operating margins on a sequential basis by 100 basis points in the quarter.  The UK R&D tax credit recorded in the third quarter represents a six month impact (as the law was signed in July 2013, but applied retroactive to April 1, 2013).  The fourth quarter of 2013 will reflect the UK R&D credit associated with costs incurred during only that quarter.  As a result, operating margins in the fourth quarter of 2013 will face a sequential headwind of approximately 100 basis points from a normalization of the UK R&D tax credit. 

Late-Stage Development ($ in millions)3Q133Q12ChangeYTD13YTD12ChangeNet Revenues

$386.4

$324.1

19.2%

$1,137.0

$966.3

17.7%Operating Income

$86.8

$64.4

34.8%

$249.3

$204.9

21.7%Operating Margin

22.5%

19.9%21.9%

21.2%Restructuring Costs

($0.5)

($0.4)($3.8)

($0.6)Operating Income, excluding items

$87.4

$64.8

34.8%

$253.1

$205.5

23.2%Operating Margin, excluding items

22.6%

20.0%22.3%

21.3% 

The Late-Stage Development segment includes central laboratory, Phase IIb-IV clinical development, and market access services.  Net revenues for the third quarter of 2013 grew 19.2% year-on-year to $386.4 million, and increased $8.6 million sequentially from the second quarter level. In the quarter, foreign exchange favorably impacted revenue growth by 160 basis points. Year-over-year growth was driven by increases of 26% in central laboratories and 14% in clinical development, while sequential revenue growth was driven by growth in central laboratories.

Operating income for the third quarter was $86.8 million on a GAAP basis and included $0.5 million in costs associated with our ongoing restructuring actions. On a pro forma basis, operating income was $87.4 million, up 34.8% year-over-year. Pro Forma operating income also increased $6.5 million sequentially. Pro forma operating margins were 22.6% for the third quarter of 2013, versus 20.0% in the third quarter of 2012 and 21.4% last quarter. The year-on-year increase in profitability was led by operating leverage in central laboratories followed by clinical development, which more than offset increased spending on strategic IT projects.

On a sequential basis, operating margins in the third quarter were positively impacted by the shift to above margin treatment of the UK R&D tax credit which added 90 basis points.  In addition, on July 1 annual salary merit increases went into effect and this was a sequential operating margin headwind of 90 basis points.  The UK R&D tax credit recorded in the third quarter represents a six month impact.  The fourth quarter of 2013 will reflect the UK R&D credit associated with costs incurred during only that quarter.  As a result, operating margins in the fourth quarter of 2013 will face a sequential headwind of approximately 45 basis points from a normalization of the UK R&D tax credit. 

Corporate InformationThe company reported third quarter adjusted net orders of $732 million. Backlog at September 30, 2013 was $6.83 billion compared to $6.73 billion at June 30, 2013 and $6.37 billion at September 30, 2012. Foreign exchange contributed $70 million to backlog growth on a sequential basis. 

Corporate expenses totaled $51.4 million in the third quarter of 2013 (including $2.8 million in restructuring costs) compared to $49.9 million last quarter (including $2.3 million in restructuring costs) and $40.9 million in the third quarter of 2012 (including $0.5 million in restructuring costs). The largest driver of the year-over-year increase in corporate expenses is spending on our strategic IT initiatives followed by higher incentive compensation expenses related to stronger-than-budgeted business performance.Cash, cash equivalents and short-term investments at September 30, 2013 were $593 million compared to $446 million at June 30, 2013 and $441 million at September 30, 2012.  Short-term debt was reduced by $60 million in the third quarter to $265 million as of September 30. As announced on October 8, Covance entered into a note purchase agreement for the private placement of $250 million in senior notes planned to be issued in November.Net Days Sales Outstanding (DSO) declined 13 days in the third quarter to 35 days at September 30, 2013 compared to 48 days at June 30, 2013 and 38 days at September 30, 2012.

Free cash flow (defined as operating cash flow less capital expenditures) for the third quarter of 2013 was $180 million, consisting of operating cash flow of $215 million less capital expenditures of $35 million.  Free cash flow year-to-date was $109 million, consisting of operating cash flow of $213 million less capital expenditures of $104 million.  In 2013, we continue to expect free cash flow to be at least $125 million, net of capital expenditures of approximately $160 million.  The free cash flow target for 2013 assumes net DSO at 40 days at December 31, 2013.

The pro forma effective tax rate in the third quarter of 28.3% was impacted by the shift to above margin treatment of the UK R&D tax credit.  Previously this credit was recorded as a reduction to income tax expense.  As a result of UK tax legislation signed in the third quarter of 2013, but effective April 1, 2013, the company now reports the UK R&D credit as an above margin expense reduction.  The impact in the third quarter was an increase in the company's effective tax rate of approximately 900 basis points, representing a six month impact.  The fourth quarter of 2013 will reflect the UK R&D credit associated with costs incurred during only that quarter.  As a result, the effective tax rate in the fourth quarter of 2013 will face a sequential tailwind of approximately 450 basis points from the third quarter level from a normalization of the UK R&D tax credit, resulting in an expected tax rate slightly below 24%.

The company's investor conference call will be webcast on October 30 at 9:00 am ET.  Management's commentary and presentation slides will be available through www.covance.com.  

Covance, with headquarters in Princeton, New Jersey, is one of the world's largest and most comprehensive drug development services companies with annual revenues greater than $2.2 billion and more than 12,000 employees located in over 60 countries.  Information on Covance's products and services, recent press releases, and SEC filings can be obtained through its website at www.covance.com.

Statements contained in this press release, which are not historical facts, such as statements about prospective earnings, savings, revenue, operations, revenue and earnings growth and other financial results are forward-looking statements pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.  All such forward-looking statements including the statements contained herein regarding anticipated trends in the company's business are based largely on management's expectations and are subject to and qualified by risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements.  These risks and uncertainties include, without limitation, competitive factors, outsourcing trends in the pharmaceutical industry, levels of industry research and development spending, the company's ability to continue to attract and retain qualified personnel, the fixed price nature of contracts or the loss or delay of large studies, risks associated with acquisitions and investments, the company's ability to increase order volume, the pace of translation of orders into revenue in late-stage development services, testing mix and geographic mix of kit receipts in central laboratories,  fluctuations in currency exchange rates, the realization of savings from the company's announced restructuring actions, the cost and pace of completion of our information technology projects and the realization of benefits therefrom,  the satisfaction of the conditions of the note purchase agreement and the closing thereof, and other factors described in the company's filings with the Securities and Exchange Commission including its Annual Report on Form 10-K and Quarterly Reports on Form 10-Q.  The company undertakes no duty to update any forward-looking statement to conform the statement to actual results or changes in the company's expectations.

Financial Exhibits Follow

 COVANCE INC.CONSOLIDATED INCOME STATEMENTSFOR THE THREE AND NINE MONTHS ENDED SEPTEMBER 30, 2013 AND 2012(Dollars in thousands, except per share data)(UNAUDITED)Three Months Ended September 30Nine Months Ended September 302013201220132012Net revenues$
,722$
544,818$   1,779,219$   1,618,441Reimbursable out-of-pocket expenses40,32852,844146,142138,174Total revenues647,050597,6621,925,3611,756,615Costs and expenses:  Cost of revenue424,857389,7241,255,3161,174,382  Reimbursable out-of-pocket expenses40,32852,844146,142138,174  Selling, general and administrative87,05294,401266,448266,031  Depreciation and amortization32,19130,10295,07287,285  Goodwill impairment charge---17,959Total costs and expenses584,428(a)567,071(c)1,762,978(b)1,683,831(d)Income from operations62,622(a)30,591(c)162,383(b)72,784(d)Other (income) expense, net:  Interest expense, net7599202,6342,353  Foreign exchange transaction loss, net8822811,9111,301  Gain on sale of investments-(1,459)(16,400)(1,459)  Impairment of equity investment---7,373  Loss on sale of business---169Other (income) expense, net1,641(258)(c)(11,855)(b)9,737(d)Income before taxes and equity investee earnings60,981(a)30,849(c)174,238(b)63,047(d)Tax expense (benefit)16,780(a)(6,971)(c)40,877(b)2,229(d)Equity investee earnings---17Net income$
44,201(a)$
37,820(c)$
33,361(b)$
,835(d)Basic earnings per share$
.81(a)$
.70(c)$
2.45(b)$
.10(d)Weighted average shares outstanding - basic54,703,76353,687,74854,524,29655,206,190Diluted earnings per share$
.78(a)$
.69(c)$
2.35(b)$
.07(d)Weighted average shares outstanding - diluted56,939,18155,201,55256,754,52756,701,280(a) Three months ended September 30, 2013 includes, as applicable, $4,893 in charges associated with restructuring and other cost reduction actions ($3,063 net of tax).(b) Nine months ended September 30, 2013 includes, as applicable, $17,076 in charges associated with restructuring and other cost reduction actions ($11,352 net of tax), and $16,400 gain on sale of investments ($10,654 net of tax).(c) Three months ended September 30, 2012 includes, as applicable, $14,072 in restructuring costs ($9,647 net of tax), $4,000 in costs associated with the settlement of an inventory supply agreement ($2,756 net of tax), $2,609 in losses at sites in wind-down ($1,821 net of tax), $1,459 gain on sale of investment ($945 net of tax) and favorable income tax items totaling $11,501.(d) Nine months ended September 30, 2012 includes, as applicable, $23,739 in restructuring costs ($16,177 net of tax), $24,781 in inventory impairment charges and costs associated with the settlement of an inventory supply agreement ($17,147 net of tax), $17,959 of goodwill impairment charges ($17,959 net of tax), $7,373 of impairment of equity investment ($7,373 net of tax), $6,424 in losses at sites in wind-down ($4,567 net of tax), $1,459 gain on sale of investment ($945 net of tax) and favorable income tax items totaling $11,501.Excluding the impact of charges associated with restructuring and other cost reduction actions, impairment charges, costs associated with the settlement of an inventory supply agreement, losses at sites in wind-down, gain on sale of investments and favorable tax items, as applicable:Income from operations$
7,515$
51,272$
79,459$
45,687Taxes on income$
8,610$
,473$
40,855$
30,269Net income $
47,264$
39,598$
34,059$
,612Basic earnings per share$
.86$
.74$
2.46$
2.02Diluted earnings per share$
.83$
.72$
2.36$
.97 COVANCE INC.CONSOLIDATED BALANCE SHEETSSEPTEMBER 30, 2013 and DECEMBER 31, 2012(Dollars in thousands)September 30December 3120132012(UNAUDITED)ASSETSCurrent Assets:Cash & cash equivalents$
482,800$
492,824Short-term investments109,794-Accounts receivable, net353,940339,558Unbilled services147,355136,878Inventory49,51649,270Deferred income taxes49,36344,903Income taxes receivable-3,642Prepaid expenses and other current assets203,200167,629Total Current Assets1,395,9681,234,704Property and equipment, net891,680891,319Goodwill109,820109,820Other assets40,84652,499Total Assets$
2,438,314$   2,288,342LIABILITIES and STOCKHOLDERS' EQUITYCurrent Liabilities:Accounts payable$
52,020$
34,430Accrued payroll and benefits143,599144,681Accrued expenses and other current liabilities104,032127,686Unearned revenue266,522255,776Short-term debt 265,000320,000Income taxes payable11,663-Total Current Liabilities842,836882,573Deferred income taxes21,18627,912Other liabilities75,84070,665Total Liabilities939,862981,150Stockholders' Equity:Common stock807791Paid-in capital836,056744,114Retained earnings1,733,9871,600,626Accumulated other comprehensive income23,96628,520Treasury stock(1,096,364)(1,066,859)Total Stockholders' Equity1,498,4521,307,192Total Liabilities and Stockholders'  Equity$
2,438,314$   2,288,342 

 COVANCE INC.CONSOLIDATED STATEMENTS OF CASH FLOWSFOR THE NINE MONTHS ENDED SEPTEMBER 30, 2013 AND 2012(Dollars in thousands)(UNAUDITED)Nine Months Ended September 3020132012Cash flows from operating activities:  Net income$
33,361$
,835  Adjustments to reconcile net income to net cash provided byoperating activities:Depreciation and amortization95,07287,285Non-cash impairment charges-44,610Non-cash compensation expense associated with employee benefitand stock compensation plans29,86329,774Deferred income tax benefit(6,787)(23,648)Gain on sale of investments(16,400)(1,459)Loss on sale of business-169Loss on disposal of property and equipment487674Equity investee earnings-(17)Changes in operating assets and liabilities, net of business sold:Accounts receivable(14,382)(10,404)Unbilled services(10,477)(27,561)Inventory(246)9,115Accounts payable17,5902,565Accrued liabilities(24,736)(1,396)Unearned revenue10,74633,374Income taxes20,228568Other assets and liabilities, net(21,474)(51,581)Net cash provided by operating activities212,845152,903Cash flows from investing activities:  Capital expenditures(103,703)(105,199)  Purchase of short-term investments(109,794)-  Proceeds from sale of investments17,7814,682  Other, net5281,006Net cash used in investing activities(195,188)(99,511)Cash flows from financing activities:  Net (repayments) borrowings under revolving credit facility(55,000)310,000  Stock issued under option plans57,1725,794  Purchase of treasury stock(29,505)(322,452)Net cash used in financing activities(27,333)(6,658)Effect of exchange rate changes on cash(348)5,535Net change in cash and cash equivalents(10,024)52,269Cash and cash equivalents, beginning of period492,824389,103Cash and cash equivalents, end of period$
482,800$
441,372 

 COVANCE INC.GAAP to Pro Forma ReconciliationQ3 2013(Dollars in thousands, except per share data)(UNAUDITED)AdjustmentsGAAP Restructuring
and Other Cost
Reduction
Activities (1)Pro FormaNet revenues$
,722$
,722Reimbursable out-of-pocket expenses40,32840,328Total revenues647,050-647,050Costs and expenses:  Cost of revenue424,857424,857  Reimbursable out-of-pocket expenses40,32840,328  Selling, general and administrative87,052(4,475)82,577  Depreciation and amortization32,191(418)31,773Total costs and expenses584,428(4,893)579,535Income from operations62,6224,89367,515Other (income) expense, net:  Interest expense, net759759  Foreign exchange transaction loss, net882882Other (income) expense, net1,641-1,641Income before taxes60,9814,89365,874Taxes on income16,7801,83018,610Net income $
44,201$
3,063$
47,264Basic earnings per share$
.81$
.06$
.86Weighted average shares outstanding - basic54,703,76354,703,76354,703,763Diluted earnings per share$
.78$
.05$
.83Weighted average shares outstanding - diluted56,939,18156,939,18156,939,181(1) Represents costs incurred to better align capacity to preclinical market demand and reduce overall cost structure. 

 COVANCE INC.GAAP to Pro Forma ReconciliationQ3 2012(Dollars in thousands, except per share data)(UNAUDITED)AdjustmentsGAAP Restructuring
Activities (1)Other
Items (2)Operating
Results at
Sites in Wind-
Down (3)Income Tax
Items (4)Pro FormaNet revenues$
544,818$
(2,967)$
541,851Reimbursable out-of-pocket expenses52,84452,844Total revenues597,662--(2,967)-594,695Costs and expenses:  Cost of revenue389,724(4,000)(4,544)381,180  Reimbursable out-of-pocket expenses52,84452,844  Selling, general and administrative94,401(12,989)(162)81,250  Depreciation and amortization30,102(1,083)(870)28,149Total costs and expenses567,071(14,072)(4,000)(5,576)-543,423Income from operations30,59114,0724,0002,609-51,272Other (income) expense, net:  Interest expense, net920920  Foreign exchange transaction loss, net281281  Gain on sale of investment(1,459)1,459-Other (income) expense, net(258)-1,459--1,201Income before taxes30,84914,0722,5412,609-50,071Taxes on income(6,971)4,42573078811,50110,473Net income $
37,820$
9,647$
,811$
,821$
(11,501)$
39,598Basic earnings per share$
.70$
.18$
.03$
.03$
(0.21)$
.74Weighted average shares outstanding - basic53,687,74853,687,74853,687,74853,687,74853,687,74853,687,748Diluted earnings per share$
.69$
.17$
.03$
.03$
(0.21)$
.72Weighted average shares outstanding - diluted55,201,55255,201,55255,201,55255,201,55255,201,55255,201,552(1) Represents costs incurred to better align capacity to preclinical market demand and reduce cost structure.(2) Consists of costs associated with the settlement of an inventory supply agreement ($4,000) and a gain on the sale of an investment $1,459.(3) Represents results of operations at sites where wind-down activities have commenced.(4) Primarily represents favorable resolutions of income tax matters. 

 COVANCE INC.GAAP to Pro Forma ReconciliationYTD Q3 2013(Dollars in thousands, except per share data)(UNAUDITED)AdjustmentsGAAP Restructuring
and Other Cost
Reduction
Activities (1)Other
Items (2)Pro FormaNet revenues$  1,779,219$  1,779,219Reimbursable out-of-pocket expenses146,142146,142Total revenues1,925,361--1,925,361Costs and expenses:  Cost of revenue1,255,3161,255,316  Reimbursable out-of-pocket expenses146,142146,142  Selling, general and administrative266,448(14,576)251,872  Depreciation and amortization95,072(2,500)92,572Total costs and expenses1,762,978(17,076)-1,745,902Income from operations162,38317,076-179,459Other (income) expense, net:  Interest expense, net2,6342,634  Foreign exchange transaction loss, net1,9111,911  Gain on sale of investments(16,400)16,400-Other (income) expense, net(11,855)-16,4004,545Income before taxes174,23817,076(16,400)174,914Taxes on income40,8775,724(5,746)40,855Net income $
33,361$
,352$
(10,654)$
34,059Basic earnings per share$
2.45$
.21$
(0.20)$
2.46Weighted average shares outstanding - basic54,524,29654,524,29654,524,29654,524,296Diluted earnings per share$
2.35$
.20$
(0.19)$
2.36Weighted average shares outstanding - diluted56,754,52756,754,52756,754,52756,754,527(1) Represents costs incurred to better align capacity to preclinical market demand and reduce overall cost structure.(2) Represents gain on sale of investments. 

 COVANCE INC.GAAP to Pro Forma ReconciliationYTD Q3 2012(Dollars in thousands, except per share data)(UNAUDITED)AdjustmentsGAAP Restructuring
Activities (1)Other
Items (2)Operating
Results at
Sites in Wind-
Down (3)Income Tax
Items (4)Pro FormaNet revenues$
,618,441$
(7,256)$  1,611,185Reimbursable out-of-pocket expenses138,174138,174Total revenues1,756,615--(7,256)-1,749,359Costs and expenses:  Cost of revenue1,174,382(24,781)(11,483)1,138,118  Reimbursable out-of-pocket expenses138,174138,174  Selling, general and administrative266,031(21,446)(384)244,201  Depreciation and amortization87,285(2,293)(1,813)83,179  Goodwill impairment charge17,959(17,959)-Total costs and expenses1,683,831(23,739)(42,740)(13,680)-1,603,672Income from operations72,78423,73942,7406,424-145,687Other (income) expense, net:  Interest expense, net2,3532,353  Foreign exchange transaction loss, net1,3011,301  Impairment of equity investment7,373(7,373)-  Gain on sale of investment(1,459)1,459-  Loss on sale of business169169Other (income) expense, net9,737-(5,914)--3,823Income before taxes and equity investee earnings63,04723,73948,6546,424-141,864Taxes on income2,2297,5627,1201,85711,50130,269Equity investee earnings1717Net income $
,835$
,177$
41,534$
4,567$
(11,501)$
,612Basic earnings per share$
.10$
.29$
.75$
.08$
(0.21)$
2.02Weighted average shares outstanding - basic55,206,19055,206,19055,206,19055,206,19055,206,19055,206,190Diluted earnings per share$
.07$
.29$
.73$
.08$
(0.20)$
.97Weighted average shares outstanding - diluted56,701,28056,701,28056,701,28056,701,28056,701,28056,701,280(1) Represents costs incurred to better align capacity to preclinical market demand and reduce cost structure.(2) Consists of inventory impairment and costs associated with the settlement of an inventory supply agreement ($24,781), goodwill impairment ($17,959), impairment of equity investment ($7,373) and a gain on the sale of an investment $1,459.(3) Represents results of operations at sites where wind-down activities have commenced.(4) Primarily represents favorable resolutions of income tax matters. 


'/>"/>
SOURCE Covance Inc.
Copyright©2012 PR Newswire.
All rights reserved


Related medicine technology :

1. Covance To Present At The William Blair 32nd Annual Growth Stock Conference
2. Covance Reports Second Quarter Pro Forma Net Revenue Of $538 Million, Pro Forma EPS Of $0.65 And Adjusted Net Orders Of $701 Million
3. Covance to Present at the Morgan Stanley Global Healthcare Conference
4. Covance Reports Third Quarter Pro Forma Net Revenue Of $542 Million, Pro Forma EPS Of $0.72 And Adjusted Net Orders Of $701 Million
5. Covance To Present At The Lazard Capital Markets 9th Annual Healthcare Conference
6. Covance Reports Fourth Quarter Pro Forma Net Revenue Of $561 Million, Pro Forma EPS Of $0.73 And Adjusted Net Orders Of $769 Million
7. Covance To Present At The Leerink Swann Global Healthcare Conference
8. Covance To Present At The Citi 2013 Global Healthcare Conference
9. Covance Inc. Invites You to Join the Webcast of Its First Quarter 2013 Financial Results Conference Call
10. Covance Expands Singapore Central Laboratory by 50 Percent to Meet Clients Increased Asia Pacific Focus
11. Covance Reports First Quarter Net Revenue Growth Of 9.3% To $580 Million, Pro Forma EPS Of $0.75 And Adjusted Net Orders Of $716 Million
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... 2016 Research and Markets has announced ... Analysis 2016 - Forecast to 2022" report to their ... contains up to date financial data derived from varied research ... trends with potential impact on the market during the next ... which comprises of sub markets, regional and country level analysis. ...
(Date:6/23/2016)... and INDIANAPOLIS , June 23, ... a Lilly Diabetes Tomorrow,s Leaders Scholarship is any indication, ... winners, announced today online at www.diabetesscholars.org by ... 1 diabetes stand in the way of academic and ... the Foundation,s scholarship program since 2012, and continues to ...
(Date:6/23/2016)... Research and Markets has announced the addition ... States, China, Japan, Brazil, United Kingdom, Germany, France, Italy, ... Surgical Procedure Volumes: Global ... surgical procedure volume data in a geographic context. The ... of growth drivers and inhibitors, including world population growth, ...
Breaking Medicine Technology:
(Date:6/24/2016)... ... June 24, 2016 , ... Marcy was in a crisis. Her son James, eight, was out ... family verbally and physically. , “When something upset him, he couldn’t control his emotions,” remembers ... would throw rocks at my other children and say he was going to kill them. ...
(Date:6/24/2016)... ... June 24, 2016 , ... ... micro-osteoperforation for accelerated orthodontic treatment. Dr. Cheng has extensive experience with all areas ... , AcceleDent, and accelerated osteogenic orthodontics. , Micro-osteoperforation is a revolutionary adjunct ...
(Date:6/24/2016)... ... 2016 , ... People across the U.S. are sharpening their pencils and honing ... contest in which patients and their families pay tribute to a genetic counselor by ... Society of Genetic Counselors (NSGC) Annual Education Conference (AEC) this September. , In ...
(Date:6/24/2016)... ... June 24, 2016 , ... Puradigm® & Innovative Solutions ... initiated cultivation and processing operations at its production facility, and opened its first ... is the manufacturer of a complete system of proactive air and surface purification ...
(Date:6/24/2016)... ... 2016 , ... Venture Construction Group (VCG) sponsors Luke’s Wings ... at the Woodmont Country Club at 1201 Rockville Pike, Rockville, Maryland, 20852. The ... members that have been wounded in battle and their families. Venture Construction Group is ...
Breaking Medicine News(10 mins):